You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Painless, Bloodless And Safe Glucose Sensing System For The Pediatric Intensive Care Unit
SBC: Fluorometrix Biomedical Company Topic: NICHDDESCRIPTION provided by applicant Studies in the pediatric intensive care unit PICU have shown that hypoglycemia hyperglycemia as well as swings in blood glucose levels are strongly associated with higher morbidity and mortality However tight glucose control has not been proven as effective In fact hypoglycemia was found to be a real danger Thus there is a need for more careful study ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
In vitro human model for individualized response to CFTR modulators
SBC: Progenra, Inc Topic: NHLBIDESCRIPTION provided by applicant The approval of the cystic fibrosis CF drug invocator for patients with the G D mutation validates CFTR modulators for improving clinical outcomes in CF For most CF patients with F del and other mutations however multi drug combination therapy will likely be necessary and sensitive biomarkers of augmented CFTR function in response to various agents ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Therapeutics for inflammatory bowel disease from the microbiome
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: 300PROJECT SUMMARY ABSTRACT Interactions between the gut microbiome and the immune system have been linked to inflammatory bowel disease IBD IBD is a chronic and progressive gastrointestinal disease characterized by uncontrolled activation of the intestinal immune system resulting in severe medical complications affecting over million patients in the United States It is a disease of high u ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of a kit for characterization of cellular energetics in single cells in cell and tissue cultures based on the measurement of the absolute magnitude of the mitochondrial membrane potential
SBC: Gerencser, Akos Topic: R41DESCRIPTION provided by applicant Altered cellular energetics contributes to human disease in general physiological aging and chronic diseases in particular including cancer neurodegeneration ischemic heart disease and type diabetes Pathological changes affecting the individual may arise only in specific cells of a tissue and potentially in a heterogeneous manner To advance basic resea ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Smart Residential Carpet for Promoting Aging in Place
SBC: BIOSENSICS LLC Topic: NIADESCRIPTION provided by applicant Aging in place or the ability of older adults to continue to live safely and economically in their own residences for as long as possible is one of the key issues of modern societies Continued population growth of older adults age will lead to significant financial and logistical burdens on the nationandapos s healthcare system As the population ages ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Antibody targeting of ADAM for treatment of triple negative breast cancer
SBC: ADECTO PHARMACEUTICALS, INC. Topic: NCIDESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Lipidated Stable BAM8-22 Offers a Promising Therapeutic for Neuropathic Pain
SBC: On Target Therapeutics, LLC Topic: 106DESCRIPTION provided by applicant Neuropathic pain is a serious health problem that affects millions of people worldwide and occurs in as much as of the general population The management of neuropathic pain in patients is complex with an estimated of individuals refractory to existing analgesic therapies The aging population the diabetes epidemic and the significant cohorts of can ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Optimized AAV Serotype Vectors for Human Gene Therapy
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Adeno associated virus AAV is a non pathogenic human parvovirus and recombinant AAV vectors have gained significant attention owing to their safety and in some cases clinical efficacy in a number of Phase I II clinical trials However relatively large vector doses are needed to achieve clinical efficacy and such high doses can lead to host immune respon ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Simvastatin nanomedicine in ARDS and sepsis
SBC: EUNOIA BIOTECH LLC Topic: 400Title Simvastatin nanomedicine in ARDS and sepsis The host response to severe infection termed sepsis affects more than million Americans yr generating annual direct costs exceeding $ billion Novel therapies are sorely needed to target maladaptive features of the host response that complement antimicrobial drugs and advances in supportive care Microcirculatory hyperpermeability may be a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health